Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
LGNDthis companyLigand Pharmaceuticals Incorporated	$310.70	29.36×	3.59×	13.64×	20.41×	-87.1%	97.5%	17.6%	46.4%	12.2%	2.4%	1.3%	0.44×	1.43×	10.01×	22.23×	0.0%	5	3.83	2	C
ABBVAbbVie Inc.	$292.30	96.41×	-123.96×	6.63×	26.61×	-55.6%	70.2%	32.8%	6.9%	-129.2%	13.0%	4.4%	-21.12×	3.62×	6.94×	0.67×	2.9%	7	2.9	1	C-
AMGNAmgen Inc.	$463.50	22.84×	20.34×	4.79×	13.11×	92.1%	70.8%	29.1%	21.0%	89.1%	13.2%	4.6%	6.31×	2.69×	3.88×	1.14×	2.9%	8	2.44	3	B+
BCRXBioCryst Pharmaceuticals, Inc.	$7.62	6.19×	-13.74×	1.87×	5.71×	-1611.4%	97.8%	39.0%	30.2%	-221.4%	105.2%	20.0%	-3.68×	1×	4.32×	2.06×	0.0%	5	-3.69	2	B-
BMYBristol-Myers Squibb Company	$62.10	15.59×	5.96×	2.28×	9.65×	275.2%	71.1%	28.5%	14.6%	38.2%	15.0%	11.7%	2.55×	2.42×	7.26×	1.26×	4.6%	7	2.7	4	A-
EXELExelixis, Inc.	$71.55	15.13×	5.48×	5.1×	12.5×	124.2%	96.4%	37.6%	33.7%	36.2%	29.7%	7.1%	0.08×	-0.34×	0×	3.56×	0.0%	6	18.06	4	A
Peer median	—	15.59×	5.48×	4.79×	12.5×	92.1%	71.1%	32.8%	21.0%	36.2%	15.0%	7.1%	0.08×	2.42×	4.32×	1.26×	2.9%	7	2.7	3	—